Isentin5 mg

Isentin 5 mg is prescribed to treat type 2 diabetes mellitus in adults to enhance glycaemic control. As monotherapy: in patients who cannot be properly managed by diet and exercise alone and for whom metformin is contraindicated owing to renal impairment or inappropriate due to intolerance. As monotherapy: in patients who cannot be properly managed by diet and exercise alone and for whom metformin is contraindicated owing to renal impairment or inappropriate due to intolerance. When diet and exercise plus metformin alone are insufficient to achieve adequate glycaemic control, combination therapy may be used. Examples include using sulphonylurea in addition to metformin when diet and exercise plus dual therapy with these drugs is insufficient to achieve adequate glycaemic control.

Dipeptidyl Peptidase-4 (DPP-4) inhibitor

Isentin 5 mg is recommended for those with type 2 diabetes mellitus to help with glycemic management. The incretin hormones GLP-1 (glucagon-like peptide-4) and GIP are degraded by the enzyme DPP-4, which is inhibited by it (glucose-dependent insulinotropic polypeptide). By boosting the release of insulin from pancreatic beta () cells in a glucose-dependent manner and inhibiting the release of glucagon from pancreatic alpha () cells into the blood, this raises the concentrations of active incretin hormones.

You should take Isentin 5 mg once a day. When given along with metformin, you should keep it constant. A lower dose of sulfonylurea may be used in conjunction with another medication to lessen the risk of hypoglycemia. Individuals with renal impairment: No dose modification is necessary. It may be taken at any time of the day with or without food.

You should take Isentin 5 mg once a day. When given along with metformin, you should keep it constant. A lower dose of sulfonylurea may be used in conjunction with another medication to lessen the risk of hypoglycemia. Individuals with renal impairment: No dose modification is necessary. It may be taken at any time of the day with or without food.

This medication does not inhibit other CYP isozymes but is a weak competitive and weak to moderate mechanism-based inhibitor of the CYP isozyme CYP3A4. It is unlikely that other medications will interact clinically meaningfully with Isentin 5 mg, and clinical investigations have shown that the drug has no clinically significant impact on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin, or oral contraceptives.

Hypersensitivity to any excipient or active ingredient.

Along with metformin and sulfonylurea, there is a chance of hypoglycemia, nasopharyngitis, cough, and pancreatitis.

B-category pregnancy. Pregnant women have not been the subject of sufficient, rigorous investigations. As a result, only use this pills during pregnancy if absolutely necessary. It may or may not enter breast milk; this is unknown.

Hypersensitivity to any excipient or active ingredient.

Keep dry and away from heat and light. Keep out of children's reach.

Dipeptidyl Peptidase-4 (DPP-4) inhibitor

Isentin 5 mg is recommended for those with type 2 diabetes mellitus to help with glycemic management. The incretin hormones GLP-1 (glucagon-like peptide-1) and GIP are degraded by the enzyme DPP-4, which is inhibited by it (glucose-dependent insulinotropic polypeptide). By boosting the release of insulin from pancreatic beta () cells in a glucose-dependent manner and inhibiting the release of glucagon from pancreatic alpha () cells into the blood, Isentin 5 mg raises the concentrations of active incretin hormones.

B-category pregnancy. Pregnant women have not been the subject of sufficient, rigorous investigations. As a result, only use Isentin 5 mg pills during pregnancy if absolutely necessary. This medication may or may not enter breast milk; this is unknown.